{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"-0.8"},{"groupId":"OG001","spread":"0.20","value":"-0.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"The disability dimension of CHAQ consisted of 20 multiple choice items about difficulty in doing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Four response categories range from 'without any difficulty'(0) to 'unable to do' (3). Mixed linear model on change from baseline in CHAQ score included treatment group, stratification factors, day of assessment and interaction between group and day as covariates. Negative change indicates improvement.","dispersionType":"Standard Error","groups":[{"description":"Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\\>37.5 kg) received two sc injections.","id":"OG000","title":"Canakinumab"},{"description":"Patients received a single dose matching placebo of canakinumab on day 1.","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients who received at least one dose of study drug. Only observed cases were used in the analysis.","reportingStatus":"POSTED","timeFrame":"At 4 week study period","title":"Change in Disability Score Over Time by Use of the CHAQ","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}